Orchestra BioMed (Nasdaq:OBIO) expects to receive up to $21 million in cash as a result of Haemonetics' recent.

Researchers have created a new noninvasive technique for performing a type of artery bypass that may change the future of ...

Piedmont Heart Institute (PHI) physicians Pradeep K. Yadav, M.D., Director of Structural Interventions, and Vinod H. Thourani, M.D., Marcus Chairman of Cardiovascular Surgery, successfully performed ...

It involves less pain, less bleeding, and there’s lower risk of infection,” said cardiothoracic surgeon Dr. Sanjay Tripathi.

A steady stream of structural trial data, approvals, reimbursement decisions, and real-world rollouts arrived in 2025.

Edwards Lifesciences stock is supported by its growth outlook and the impact of clinical advances. See why investors should await better entry points.

IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced the company’s SAPIEN M3 mitral valve replacement system is the first transcatheter therapy utilizing a transseptal approach ...

Edwards Lifesciences has claimed an FDA approval for its Sapien M3 transcatheter mitral valve replacement system—marking the agency’s first in this type of implant that takes a potentially safer route ...

Developments shaping the medtech industry in 2025 offer a glimpse of what may unfold as we head into the new year.

Background Recurrent mitral regurgitation (MR) remains a major limitation of mitral valve (MV) repair in patients with advanced degenerative MR (asDMR) and left ventricular (LV) enlargement. We ...

Artificial intelligence-driven diagnostics, 3D echocardiography, and fusion imaging will enhance mitral regurgitation (MR) assessment and procedural planning. Earlier, individualized intervention ...